STUDY OF SETIPIPRANT TABLETS IN ANDROGENETIC ALOPECIA IN MALES WITH A COMPARATOR ARM

What we are studying

Multicenter, randomized, double-blind, placebo-controlled study designed to determine the effect of treatment with setipiprant tablets 1000 mg BID on scalp hair growth. The study is approximately 32 weeks long with participants being randomized into one of three groups: Group taking Setipiprant tablets 1000mg BID, Group taking placebo BID, or Group taking Finasteride 1mg once/day. The three groups will take their regimens for 24 weeks. Eligible non-PK subjects will be randomly assigned to all three groups. PK subjects will be randomly assigned to either the setipiprant tablets or placebo groups. There are 7 scheduled study visits.

Who is Eligible

  • Genders:
    • Men
  • Races:
    • White
    • African American
  • Not Hispanic or Latino
  • Ages 18 - 41

Eligibility Criteria

  • Must have androgenetic alopecia

What is involved

  • Photography six visits
  • Vital signs and height 7 visits
  • Physical exam 3 visits
  • Microdot tattoo 1 visit
  • Subject assessments 6 visits
  • ECG 4 visits
  • Lab draws 6 visits
  • Urine drug screen 1 visit

Compensation

$50 for Each Completed Visit or a Total of $350

Contact Information

Study Coordinator
Dermatology Clinical Studies
Email
[email protected]
Phone
-3775
Principal Investigator
Amy McMichael, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.